Literature DB >> 22837197

TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.

Victoria Jeisy-Scott1, Jin Hyang Kim, William G Davis, Weiping Cao, Jacqueline M Katz, Suryaprakash Sambhara.   

Abstract

Recognition of pathogen-associated molecular patterns by pattern recognition receptors of the innate immune system is crucial for the initiation of innate and adaptive responses and for immunological memory. We investigated the role of TLR7 in the induction of adaptive immunity and long-term memory following influenza virus infection and vaccination in C57BL/6 mice. During infection with influenza A/PR8/34 virus, the absence of either TLR7 or MyD88 leads to reduced virus-specific antibodies in the serum and antibody-secreting cells in their secondary lymphoid organs, particularly in bone marrow. In spite of this, the absence of TLR7/MyD88 signaling did not impair the production of protective antibodies. Following immunization with the 2009 pandemic inactivated split vaccine, TLR7(-/-) mice had significantly lower levels of germinal center formation, antibody-secreting cells, and circulating influenza virus-specific antibodies than control animals. Consequently, TLR7(-/-) mice failed to develop protective immunological memory upon challenge. Furthermore, the immunogenicity of the split vaccine was likely due to TLR7 recognition of virion RNA, as its removal from the split vaccine significantly reduced the levels of influenza virus-specific antibodies and compromised the vaccine protective efficacy in mice. Taken together, our data demonstrate that TLR7 plays an important role in vaccine-induced humoral immune responses to influenza virus through the interaction with viral RNA present in the split vaccine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22837197      PMCID: PMC3457183          DOI: 10.1128/JVI.01064-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses.

Authors:  Katja Fink; Karl S Lang; Nataly Manjarrez-Orduno; Tobias Junt; Beatrice M Senn; Martin Holdener; Shizuo Akira; Rolf M Zinkernagel; Hans Hengartner
Journal:  Eur J Immunol       Date:  2006-08       Impact factor: 5.532

2.  MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination.

Authors:  Sang-Moo Kang; Dae-Goon Yoo; Min-Chul Kim; Jae-Min Song; Min-Kyung Park; Eunju O; Fu-Shi Quan; Shizuo Akira; Richard W Compans
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

3.  Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.

Authors:  S Sambhara; A Kurichh; R Miranda; T Tumpey; T Rowe; M Renshaw; R Arpino; A Tamane; A Kandil; O James; B Underdown; M Klein; J Katz; D Burt
Journal:  Cell Immunol       Date:  2001-08-01       Impact factor: 4.868

4.  Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes.

Authors:  Shohei Koyama; Taiki Aoshi; Takeshi Tanimoto; Yutaro Kumagai; Kouji Kobiyama; Takahiro Tougan; Kazuo Sakurai; Cevayir Coban; Toshihiro Horii; Shizuo Akira; Ken J Ishii
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

5.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

6.  Oil-in-water emulsion adjuvant with influenza vaccine in young children.

Authors:  Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

7.  Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice.

Authors:  Victoria Jeisy-Scott; William G Davis; Jenish R Patel; John Bradford Bowzard; Wun-Ju Shieh; Sherif R Zaki; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  PLoS One       Date:  2011-09-23       Impact factor: 3.240

Review 8.  Making better influenza virus vaccines?

Authors:  Peter Palese
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

9.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

10.  Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Authors:  Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede
Journal:  PLoS Pathog       Date:  2008-08-29       Impact factor: 6.823

View more
  36 in total

1.  Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults.

Authors:  Subhasis Mohanty; Samit R Joshi; Ikuyo Ueda; Jean Wilson; Tamara P Blevins; Barbara Siconolfi; Hailong Meng; Lesley Devine; Khadir Raddassi; Sui Tsang; Robert B Belshe; David A Hafler; Susan M Kaech; Steven H Kleinstein; Mark Trentalange; Heather G Allore; Albert C Shaw
Journal:  J Infect Dis       Date:  2014-11-02       Impact factor: 5.226

Review 2.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

Review 3.  Innate immunity to influenza virus infection.

Authors:  Akiko Iwasaki; Padmini S Pillai
Journal:  Nat Rev Immunol       Date:  2014-05       Impact factor: 53.106

Review 4.  Paradoxical changes in innate immunity in aging: recent progress and new directions.

Authors:  Ruth R Montgomery; Albert C Shaw
Journal:  J Leukoc Biol       Date:  2015-07-17       Impact factor: 4.962

Review 5.  How the Respiratory Epithelium Senses and Reacts to Influenza Virus.

Authors:  Kambez H Benam; Laura Denney; Ling-Pei Ho
Journal:  Am J Respir Cell Mol Biol       Date:  2019-03       Impact factor: 6.914

6.  Biological sex affects vaccine efficacy and protection against influenza in mice.

Authors:  Ashley L Fink; Kyrra Engle; Rebecca L Ursin; Wan-Yee Tang; Sabra L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

7.  Cytokine production in whole-blood cultures following immunization with an influenza vaccine.

Authors:  Tetsuo Nakayama; Takuji Kumagai; Yasuyo Kashiwagi; Hironori Yoshii; Kenta Honjo; Ritsuko Kubota-Koketsu; Yoshinobu Okuno; Shigeru Suga
Journal:  Hum Vaccin Immunother       Date:  2018-08-28       Impact factor: 3.452

8.  The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.

Authors:  Marlena M Westcott; Elene A Clemens; Beth C Holbrook; S Bruce King; Martha A Alexander-Miller
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

9.  Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB/c mice.

Authors:  Anna J X Zhang; Can Li; Kelvin K W To; Hou-Shun Zhu; Andrew C Y Lee; Chuan-Gen Li; Jasper F W Chan; Ivan F N Hung; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2014-02-12

10.  Acute clearance of human metapneumovirus occurs independently of natural killer cells.

Authors:  Sherry C Wen; Sharon J Tollefson; Monika Johnson; Pavlo Gilchuk; Kelli L Boyd; Bryan Shepherd; Sebastian Joyce; John V Williams
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.